Harvard Bioscience
HBIO
HBIO
99 hedge funds and large institutions have $232M invested in Harvard Bioscience in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 35 increasing their positions, 31 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
3.48% more ownership
Funds ownership: 66.3% → 69.78% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
99
Holding in Top 10
1
Calls
$35K
Puts
$18K
Top Buyers
| 1 | +$3.35M | |
| 2 | +$3.35M | |
| 3 | +$2.87M | |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$1.72M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.47M |
Top Sellers
| 1 | -$3.96M | |
| 2 | -$1.97M | |
| 3 | -$1.67M | |
| 4 |
Renaissance Technologies
New York
|
-$1.62M |
| 5 |
ACM
Archon Capital Management
Seattle,
Washington
|
-$1.14M |